Fusion partners to ALK included TPM3, NPM1, CAP-Gly domain-containing linker protein 1 (CLIP1), translocated promoter region (TPR), general transcription factor 3C polypeptide 2(GTF3C2), and dynactin (DCTN1), with the latter two representing new oncogenic fusions not previously reported to participate in cancer pathogenesis [104,105,106,107]. Here, TPM3 is linked to cancer.